bioRxiv · 10.1101/2025.02.01.636056
SVCFit: Inferring structural variant cellular fraction in tumors
Abstract
Therapeutic pressure shapes tumor evolution by selecting for subclones with distinct genomic architectures. In metastatic castration-resistant prostate cancer (mCRPC), structural variants (SVs) are central to this process but rarely incorporated into clonal reconstruction from bulk DNA sequencing. We describe SVCFit, a computational framework that estimates the cellular fraction of diverse SV classes from whole-genome sequencing and uses these estimates to reconstruct clonal evolutionary relationships. SVCFit explicitly models SV-type-specific breakpoint and breakend patterns and accounts for local copy-number context, enabling accurate SV cellular-fraction estimation across heterogeneous tumor genomes. On simulated datasets and in silico mixtures of metastatic prostate cancer samples, SVCFit achieves lower estimation error than SVclone, the current state-of-the-art for bulk-sequencing SV cellular-fraction estimation. Applied to longitudinal whole-genome sequencing from patients with mCRPC treated with bipolar androgen therapy, SVCFit reveals marked treatment-associated clonal reconfiguration, including contraction of highly rearranged subclones and expansion of resistant populations defined by distinct structural alterations. By enabling reconstruction of SV-defined clonal architecture from routine whole-genome sequencing, SVCFit expands the toolkit for studying tumor evolution under therapy in precision oncology. The COMBAT trial that provided these samples is registered on ClinicalTrials.gov (NCT03554317; first posted 13 June 2018).
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Liu, Y., Lai, J., Wood, L. D., Karchin, R.. 2025-02-03. SVCFit: Inferring structural variant cellular fraction in tumors. https://doi.org/10.1101/2025.02.01.636056
Cite the original work for its findings. Save a collection to share your selection of sources.